Abiopharma

🔍 Raben David (Executive)

Company: Bicara Therapeutics Inc. (BCAX)

Report Date: 2026-03-25

Detailed Transactions and Holdings:

• Acquired 5,500 shares of Common Stock at $3.7898 per share (Direct)
  Date: 2026-03-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 60,786.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,500 shares of Common Stock at $18.9508 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,286.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 5,500 shares of Stock Option (Right to Buy) at $3.7898 per share (Derivative)
  Date: 2026-03-25 | Code: M | Expires: 2023-08-08 | equity_swap_involved: 0 | shares_owned_after: 47,413.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
• F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.55 to $19.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
• F3: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.